<DOC>
	<DOCNO>NCT00409591</DOCNO>
	<brief_summary>The purpose study compare efficacy two dos nevirapine ( NVP ) give infant lopinavir/ritonavir ( LPV/r ) 28 week gestation single dose ( SD ) NVP give mother plus two dos infant , addition zidovudine ( ZDV ) prophylaxis ( 28 week ' gestation one week ZDV neonates ) prevention mother-to-child transmission HIV-1 .</brief_summary>
	<brief_title>Maternal/Infant Peripartum NVP , Versus Infant Only Peripartum NVP , Maternal LPV/r Addition Standard ZDV Prophylaxis Prevention Perinatal ( PMTCT ) HIV Thailand</brief_title>
	<detailed_description>Multicenter , placebo-controlled , double blind , clinical trial non immunocompromised woman receive ZDV prophylaxis regimen 28 week gestation , recommend Thailand , randomize one two arm : Arm 1 : NVP-NVP : - In woman , one NVP 200 mg tablet onset labor+ ; - In neonate , NVP oral suspension 6 mg delivery room immediately birth plus second dose 48 72 hours+++ Arm 2 : PL-NVP : - In woman , one placebo tablet onset labor++ ; - In neonate , NVP oral suspension 6 mg delivery room immediately birth plus second dose 48 72 hours+++ Arm 3 : LPV/r : - In woman , LPV/r 400/100 mg bid 28 week ' gestation delivery - woman Arm 1 also receive 7-day ZDV 300mg bid plus 3TC 150mg bid delivery . ++women Arm 2 also receive 7-day ( ZDV+3TC ) Placebo delivery . +++If new bear weight less 2500 g , nevirapine administer 2 mg./1 kg ( As per Thai Guideline ) . All infant receive ZDV least one week . Follow-up woman infant carry outpatient basis except delivery first three day delivery . Mothers infant followed-up 24 month delivery . Note : The study stop data unblinded upon DSMB recommendation September 2010 change Thai PMTCT guideline recommend use HAART HIV infect pregnant woman regardless CD4 count . At time unblinding 435 pregnant woman enrol follow-up woman child continue .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>PreEntry Criteria Evidence HIV infection ( document two HIV antibody test two different date ) Intend follow study site duration study At least 18 year old Written inform consent . Women eligible study meet preentry criterion Evidence HIV infection , document two serology test obtain two different date ; 28 36 week gestational age ; antiretroviral naïve except exposure ZDV prophylaxis PMTCT ; CD4 count 250 cells/mm3 ( within 4 month prior randomization ) agreement breastfeed ; consent participate follow duration study ; follow laboratory value within 14 day prior randomization : hemoglobin &gt; 8.5 mg/dl ; absolute neutrophil count &gt; 750 cells/mm3 ; platelet &gt; 50,000 cells/mm3 ; SGPT ≤ 5 time upper limit normal ; serum creatinine ≤ 1.5 time upper limit normal ( woman serum creatinine &gt; 1.5 time upper limit normal must measure eighthour urine creatinine clearance &gt; 70 ml/min ) . Exclusion criterion : Evidence preexist fetal anomaly incompatible life ; patient meet criterion Classes III/IV WHO classification HIVassociated clinical disease ; know hypersensitivity benzodiazepine ; active tuberculosis ; concurrent participation clinical trial ; receipt benzodiazepine antiretroviral agent ZDV ; uncontrolled hypertension ; anticoagulant therapy magnesium sulfate within 2 week enrollment need labor delivery . If condition occur randomization , woman exclude study drug dose . Women CD4 count low 250 cells/mm3 exclude study offer HAART context national program .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Thailand</keyword>
	<keyword>Developing Countries</keyword>
	<keyword>Prophylaxis</keyword>
	<keyword>Mother-to-child transmission</keyword>
	<keyword>HIV-1</keyword>
	<keyword>HIV-1 infection</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>